Financial Data and Key Metrics Changes - In 2025, SIGA reported total product revenues of approximately $88 million, which includes $53 million from oral TPOXX, $26 million from IV TPOXX, and $6 million from international oral TPOXX sales [3][9] - The company achieved a pretax operating income of approximately $24 million and a net income of approximately $23 million for the year, resulting in a fully diluted income per share of $0.32 [10] - As of December 31, 2025, SIGA maintained a strong cash position with approximately $155 million in cash and no debt [10] Business Line Data and Key Metrics Changes - The primary revenue driver for SIGA in 2025 was product deliveries to the U.S. Strategic National Stockpile (SNS) under the BARDA contract, which accounted for the majority of product revenues [9] - The company secured $27 million in funding to support pediatric formulation development and IV technology transfer efforts during 2025 [4] Market Data and Key Metrics Changes - SIGA continues to engage with international governments and stakeholders to strengthen health security, with a recent $13 million order from a country in the Asia-Pacific region [5][19] - The company is actively discussing stockpiling of TPOXX with various potential customers globally, reflecting an increased focus on preparedness strategies due to rising biothreat risks [5][20] Company Strategy and Development Direction - SIGA's strategy focuses on supporting global preparedness for biological threats, particularly smallpox, through sustained investment and stockpiling of antiviral treatments [2][4] - The company aims to maintain financial strength while advancing strategic initiatives that support long-term value creation [8] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of readiness in the face of heightened geopolitical risks and biological threats, emphasizing the critical role of TPOXX in emergency situations [3] - The company expects to continue its productive relationship with the U.S. government and anticipates a new procurement contract to further support stockpiling efforts [4][15] Other Important Information - The European Medicines Agency (EMA) is expected to meet in March to issue a recommendation regarding the marketing authorization of Tecovirimat SIGA, with expectations of a positive benefit-risk balance [6] - SIGA is advancing its pediatric program to develop an oral suspension formulation for children, with a phase 1 study recently initiated [8] Q&A Session Summary Question: Update on the timing of the next U.S. government RFP for TPOXX - Management indicated that smallpox preparedness remains a focus for the U.S. government, but no specific timing details for the next RFP were available [14][15] Question: Capital allocation priorities looking ahead - Management stated that capital management will remain disciplined and flexible, with no immediate updates on special cash dividends [16] Question: Openness to acquisitions or in-licensing opportunities - Management confirmed that the company is open to pursuing acquisitions or in-licensing opportunities while maintaining a disciplined and strategic approach [17] Question: Details on the recent $13 million TPOXX order - Management noted that the order is from a repeat customer under a multi-year contract, but specific details could not be disclosed for security reasons [19][20] Question: Expectations for additional international orders - Management expressed that while additional international sales may occur in 2026, the processes can be complex and time-consuming [20]